000137573 001__ 137573
000137573 005__ 20240229111724.0
000137573 0247_ $$2doi$$a10.1016/j.kint.2018.06.006
000137573 0247_ $$2pmid$$apmid:30190172
000137573 0247_ $$2ISSN$$a0085-2538
000137573 0247_ $$2ISSN$$a1523-1755
000137573 0247_ $$2ISSN$$a2157-1716
000137573 0247_ $$2ISSN$$a2157-1724
000137573 0247_ $$2altmetric$$aaltmetric:47703920
000137573 037__ $$aDKFZ-2018-01453
000137573 041__ $$aeng
000137573 082__ $$a610
000137573 1001_ $$aMicakovic, Tamara$$b0
000137573 245__ $$aThe angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus.
000137573 260__ $$aBasingstoke$$bNature Publishing Group$$c2018
000137573 3367_ $$2DRIVER$$aarticle
000137573 3367_ $$2DataCite$$aOutput Types/Journal article
000137573 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550485621_708
000137573 3367_ $$2BibTeX$$aARTICLE
000137573 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137573 3367_ $$00$$2EndNote$$aJournal Article
000137573 520__ $$aDiabetic nephropathy correlates more closely to defective mitochondria and increased oxidative stress in the kidney than to hyperglycemia. A key driving factor of diabetic nephropathy is angiotensin II acting via the G-protein-coupled cell membrane type 1 receptor. The present study aimed to investigate the role of the angiotensin II type 2 receptor (AT2R) at the early stages of diabetic nephropathy. Using receptor binding studies and immunohistochemistry we found that the mitochondria in renal tubules contain high-affinity AT2Rs. Increased renal mitochondrial AT2R density by transgenic overexpression was associated with reduced superoxide production of isolated mitochondria from non-diabetic rats. Streptozotocin-induced diabetes (28 days) caused a drop in the ATP/oxygen ratio and an increase in the superoxide production of isolated renal mitochondria from wild-type diabetic rats. This correlated with changes in the renal expression profile and increased tubular epithelial cell proliferation. AT2R overexpression in tubular epithelial cells inhibited all diabetes-induced renal changes including a drop in mitochondrial bioenergetics efficiency, a rise in mitochondrial superoxide production, metabolic reprogramming, and increased proliferation. Thus, AT2Rs translocate to mitochondria and can contribute to reno-protective effects at early stages of diabetes. Hence, targeted AT2R overexpression in renal cells may open new avenues to develop novel types of drugs preventing diabetic nephropathy.
000137573 536__ $$0G:(DE-HGF)POF3-322$$a322 - Genetics and Pathophysiology (POF3-322)$$cPOF3-322$$fPOF III$$x0
000137573 588__ $$aDataset connected to CrossRef, PubMed,
000137573 7001_ $$aPapagiannarou, Stamatia$$b1
000137573 7001_ $$aClark, Euan$$b2
000137573 7001_ $$aKuzay, Yalcin$$b3
000137573 7001_ $$aAbramovic, Katarina$$b4
000137573 7001_ $$aPeters, Jörg$$b5
000137573 7001_ $$aSticht, Carsten$$b6
000137573 7001_ $$aVolk, Nadine$$b7
000137573 7001_ $$aFleming, Thomas$$b8
000137573 7001_ $$aNawroth, Peter$$b9
000137573 7001_ $$aHammes, Hans-Peter$$b10
000137573 7001_ $$aAlenina, Natalia$$b11
000137573 7001_ $$0P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aGröne, Hermann-Josef$$b12$$udkfz
000137573 7001_ $$aHoffmann, Sigrid Christa$$b13
000137573 773__ $$0PERI:(DE-600)2007940-0$$a10.1016/j.kint.2018.06.006$$gp. S0085253818304423$$n5$$p937-950$$tKidney international$$v94$$x0085-2538$$y2018
000137573 909CO $$ooai:inrepo02.dkfz.de:137573$$pVDB
000137573 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000137573 9131_ $$0G:(DE-HGF)POF3-322$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vGenetics and Pathophysiology$$x0
000137573 9141_ $$y2018
000137573 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137573 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137573 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137573 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bKIDNEY INT SUPPL : 2015
000137573 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000137573 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000137573 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000137573 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137573 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137573 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000137573 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000137573 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000137573 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137573 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bKIDNEY INT : 2015
000137573 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bKIDNEY INT SUPPL : 2015
000137573 9201_ $$0I:(DE-He78)G130-20160331$$kG130$$lZelluläre und Molekulare Pathologie$$x0
000137573 980__ $$ajournal
000137573 980__ $$aVDB
000137573 980__ $$aI:(DE-He78)G130-20160331
000137573 980__ $$aUNRESTRICTED